Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUCT trial in newly diagnosed ulcerative colitis
2024-519891-17-00Phase 2Authorised
- Sponsor
- University Hospital of North Norway
- Start
- Jun 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of tofacitinib, filgotinib, vedolizumab, ozanimod, adalimumab and 5 more in autoimmune colitis, sponsored by University Hospital of North Norway. Primary endpoints: Deep remission at 1 year and Need for biologic therapy or surgery during first year. Planned start Jun 2025; status: authorised.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2024-519891-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519891-17-00.